Quoin Pharmaceuticals (ADR) (QNRX)
Developing topical therapies for rare genetic skin diseases.
Something off on this page? Send us feedback.
Develops topical therapies for rare genetic skin diseases, led by QRX003 for Netherton Syndrome, through an outsourced clinical and manufacturing model; it has no approved products or revenue.
Develops topical therapies for rare genetic skin diseases with limited or no approved treatments. Its lead asset, QRX003, is a serine-protease-inhibitor lotion in late-stage development for Netherton Syndrome and has an additional IND-cleared program in Peeling Skin Syndrome. QRX008 and QRX009 are earlier research programs for scleroderma and topical rapamycin applications.
Runs a lean internal organization that supervises outside clinical researchers, investigators and contract manufacturers. If approved, it plans direct sales in the United States, Western Europe and Japan, using regional partnerships elsewhere.
Has no approved or commercialized products, so revenue depends on clinical results, regulatory approval, financing and licensed technology from Skinvisible. QRX003 is its sole late-stage asset.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $10.8M · Total debt $0 · Total assets $12.0M · Shareholders' equity $3.9M
- Revenue
- $0
- Operating income
- −$5.6M
- Net income
- −$5.5M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 49.16% | 2.37M ADS | |
| Insiders6 holders · as of Sep 1, 2026 | 5.81% | 279.8K ADS | |
| Otherremainder | 45.03% | 2.17M ADS |
4.82M ADS (1 ADS = 15 ordinary shares) as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (4.82M in the company's Sep 3, 2026 report, 2.01M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Ikarian Capital, LLCInstitution | 8.78% | 211,538 ADS · 211,538 ADS | 13Fas of Mar 31, 2026 |
Dauntless Investment Group, LLCInstitution | 8.16% | 196,592 ADS · 196,592 ADS | 13Fas of Mar 31, 2026 |
Summittx Capital, L.P.Institution | 4.16% | 100,300 ADS · 100,300 ADS | 13Fas of Mar 31, 2026 |
Velan Capital Investment Management LPInstitution | 3.52% | 84,849 ADS · 84,849 ADS | 13Fas of Mar 31, 2026 |
Woodline Partners LPInstitution | 3.30% | 79,582 ADS · 79,582 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 31, 2026 | Michael Myers | director, officer: Chief Executive Officer | +30,735 | $5.29 |
| Aug 31, 2026 | Denise P. Carter | director, officer: Chief Operating Officer | +30,735 | $5.29 |
| Aug 31, 2026 | Anthony James Culverwell | director | +9,219 | $5.29 |
| Aug 31, 2026 | Sally Bridget Lawlor | officer: Chief Financial Officer | +15,366 | $5.29 |
| Oct 14, 2025 | Dennis Langer | director | +75,760 | $10.53 |
- BioCryst Pharmaceuticals
Netherton head-to-head: QRX003 lotion versus BCX17725.
- Azitra
Netherton head-to-head: QRX003 lotion versus ATR-12.
- Sanofi (ADR)
Systemic biologic alternative for Netherton skin inflammation.
- Sol-Gel Technologies
Topical rare-dermatology overlap in planned Gorlin treatment.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Quoin Pharmaceuticals (ADR) | $6.53 | −3.98% | $13.5M | — | — | — | — |
| BioCryst Pharmaceuticals | $10.17 | −0.10% | $2.58B | — | 19.4 | 2.7 | +33.6% |
| Azitra | $0.1826 | +3.99% | $1.9M | — | — | — | — |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Sol-Gel Technologies | $69.76 | −0.95% | $230.2M | — | — | 128.3 | −96.6% |
| Median | 78.2 | 19.4 | 2.7 | +11.2% |